立体定向体部放射治疗（SBRT）用于复发性非小细胞肺癌（NSCLC）。
Stereotactic Body Radiation Therapy (SBRT) for Recurrent Non-small Cell Lung Cancer (NSCLC).
作者信息
Janssen Stefan, Käsmann Lukas, Rudat Volker, Rades Dirk
机构信息
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany Medical Practice for Radiotherapy and Radiation Oncology, Hannover, Germany.
Department of Radiation Oncology, University of Lübeck, Lübeck, Germany.
出版信息
Anticancer Res. 2016 Feb;36(2):825-8.
AIM
For local recurrence of non-small cell lung cancer (NSCLC), stereotactic body radiation therapy (SBRT) has become increasingly popular. Many patients with recurrent NSCLC are unable to receive high-dose SBRT [biologically effective dose (BED) >100 Gy] due to poor performance status and potential normal tissue damage.
PATIENTS AND METHODS
Thirty-one patients receiving lower-dose SBRT with a BED of 57.6 to 96.0 Gy, were analyzed for local control, freedom from distant progression and survival.
RESULTS
In the entire series, local control rates were 96% at 1, 2 and 3 years. Freedom from distant progression rates were 74%, 65% and 65%, respectively, and survival rates were 87%, 65% and 65%, respectively. On multivariate analysis, freedom from distant progression was significantly associated with absence of distant metastases (p=0.009), and survival with BED >75 Gy (p=0.039).
CONCLUSION
SBRT with BED <100 Gy provided very promising outcomes when administered for recurrent NSCLC. A BED >75 Gy is recommended, which was superior to lower doses.
目的
对于非小细胞肺癌（NSCLC）的局部复发，立体定向体部放射治疗（SBRT）越来越受欢迎。许多复发性NSCLC患者由于身体状况差和潜在的正常组织损伤，无法接受高剂量SBRT[生物等效剂量（BED）>100 Gy]。
患者与方法
分析31例接受BED为57.6至96.0 Gy的低剂量SBRT患者的局部控制、无远处进展和生存率。
结果
在整个系列中，1年、2年和3年的局部控制率分别为96%。无远处进展率分别为74%、65%和65%，生存率分别为87%、65%和65%。多因素分析显示，无远处进展与无远处转移显著相关（p=0.009），生存率与BED>75 Gy相关（p=0.039）。
结论
对于复发性NSCLC，给予BED<100 Gy的SBRT可提供非常有前景的结果。建议使用BED>75 Gy，其效果优于较低剂量。
Zotero 插件